Search Results - "UHM, Joon H"

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis by Johnson, Derek R., Leeper, Heather E., Uhm, Joon H.

“…BACKGROUND Bevacizumab received US Food and Drug Administration approval for use in recurrent glioblastoma based on promising radiographic response data, but…”
Get full text

IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model by Tripathi, Shashwat, Vivas-Buitrago, Tito, Domingo, Ricardo A, Biase, Gaetano De, Brown, Desmond, Akinduro, Oluwaseun O, Ramos-Fresnedo, Andres, Sherman, Wendy, Gupta, Vivek, Middlebrooks, Erik H, Sabsevitz, David S, Porter, Alyx B, Uhm, Joon H, Bendok, Bernard R, Parney, Ian, Meyer, Fredric B, Chaichana, Kaisorn L, Swanson, Kristin R, Quiñones-Hinojosa, Alfredo

“…Recent studies have proposed resection of the T2 FLAIR hyperintensity beyond the T1 contrast enhancement (supramarginal resection [SMR]) for IDH-wild-type…”
Get full text

Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial by Galanis, Evanthia, Dooley, Katharine E., Keith Anderson, S., Kurokawa, Cheyne B., Carrero, Xiomara W., Uhm, Joon H., Federspiel, Mark J., Leontovich, Alexey A., Aderca, Ileana, Viker, Kimberly B., Hammack, Julie E., Marks, Randolph S., Robinson, Steven I., Johnson, Derek R., Kaufmann, Timothy J., Buckner, Jan C., Lachance, Daniel H., Burns, Terry C., Giannini, Caterina, Raghunathan, Aditya, Iankov, Ianko D., Parney, Ian F.

“…Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this…”
Get full text

Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients by Tanaka, Shota, Meyer, Fredric B, Buckner, Jan C, Uhm, Joon H, Yan, Elizabeth S, Parney, Ian F

“…Optimum management for elderly patients with newly diagnosed glioblastoma (GBM) in the temozolomide (TMZ) era is not well defined. The object of this study was…”
Get full text

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era by Uhm, Joon H., MD, Porter, Alyx B., MD

“…Abstract The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward…”
Get full text

Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia by Strati, Paolo, Uhm, Joon H, Kaufmann, Timothy J, Nabhan, Chadi, Parikh, Sameer A, Hanson, Curtis A, Chaffee, Kari G, Call, Timothy G, Shanafelt, Tait D

“…Abroad array of conditions can lead to neurological symptoms in chronic lymphocytic leukemia patients and distinguishing between clinically significant…”
Get full text

Central Nervous System Tumors by Buckner, Jan C., MD, Brown, Paul D., MD, O'Neill, Brian P., MD, Meyer, Fredric B., MD, Wetmore, Cynthia J., MD, PhD, Uhm, Joon H., MD

“…Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually. Although more than half of these tumors are…”
Get full text

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 by Brown, Paul D, Krishnan, Sunil, Sarkaria, Jann N, Wu, Wenting, Jaeckle, Kurt A, Uhm, Joon H, Geoffroy, Francois J, Arusell, Robert, Kitange, Gaspar, Jenkins, Robert B, Kugler, John W, Morton, Roscoe F, Rowland, Jr, Kendrith M, Mischel, Paul, Yong, William H, Scheithauer, Bernd W, Schiff, David, Giannini, Caterina, Buckner, Jan C

“…Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance…”
Get full text

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074 by Uhm, Joon H., M.D, Ballman, Karla V., Ph.D, Wu, Wenting, Ph.D, Giannini, Caterina, M.D, Krauss, J.C., M.D, Buckner, Jan C., M.D, James, C.D., Ph.D, Scheithauer, Bernd W., M.D, Behrens, Robert J., M.D, Flynn, Patrick J., M.D, Schaefer, Paul L., M.D, Dakhill, Shaker R., M.D, Jaeckle, Kurt A., M.D

“…Purpose Amplification of the epidermal growth factor receptor (EGFR) gene represents one of the most frequent gene alterations in glioblastoma (GBM). In the…”
Get full text

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme by Sarkaria, Jann N., M.D, Galanis, Evanthia, M.D, Wu, Wenting, Ph.D, Peller, Patrick J., M.D, Giannini, Caterina, M.D, Brown, Paul D., M.D, Uhm, Joon H., M.D, McGraw, Steven, M.D, Jaeckle, Kurt A., M.D, Buckner, Jan C., M.D

“…Background The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. On the basis of…”
Get full text

Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion by Toussaint, 3rd, L Gerard, Nilson, Allan E, Goble, Jennie M, Ballman, Karla V, James, C David, Lefranc, Florence, Kiss, Robert, Uhm, Joon H

“…High-grade gliomas, including glioblastomas (GBMs), are recalcitrant to local therapy in part because of their ability to invade the normal brain parenchyma…”
Get full text

Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report by Himes, Benjamin T, Ruff, Michael W, Van Gompel, Jaimie J, Park, Sean S, Galanis, Evanthia, Kaufmann, Timothy J, Uhm, Joon H

“…The authors present the case of a man with a papillary craniopharyngioma, first diagnosed at 47 years of age, who experienced multiple recurrences. Review of…”
Get full text

Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience by Neth, Bryan J., Webb, Mason J., White, Jessica, Uhm, Joon H., Pichurin, Pavel N., Sener, Ugur

“…Purpose Belzutifan is a selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a) that has emerged as a targeted therapy option for Von Hippel–Lindau…”
Get full text

A case series of osseous metastases in patients with glioblastoma by Webb, Lauren Michelle, Webb, Mason J, Campian, Jian L, Caron, Samantha J, Ruff, Michael W, Uhm, Joon H, Sener, Ugur

“…Extracranial metastases occur in <2% of cases of glioblastoma (GBM). When metastases do occur, bone is the most common destination. Herein, we review clinical…”
Get full text

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial by GALANIS, Evanthia, KEITH ANDERSON, S, KAUFMANN, Timothy J, BUCKNER, Jan C, LAFKY, Jackie M, UHM, Joon H, GIANNINI, Caterina, KUMAR, Shaji K, KIMLINGER, Teresa K, NORTHFELT, Donald W, FLYNN, Patrick J, JAECKLE, Kurt A

“…We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a…”
Get full text

Neuro-oncology: Implications of the molecular era by Ruff, Michael W, Uhm, Joon H, Benarroch, Eduardo E

“…The field of neuro-oncology has recently experienced a renaissance in the understanding of the molecular underpinnings and pathophysiology of glioma. Genetic…”
Get full text

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K by Ma, Daniel J, Galanis, Evanthia, Anderson, S Keith, Schiff, David, Kaufmann, Timothy J, Peller, Patrick J, Giannini, Caterina, Brown, Paul D, Uhm, Joon H, McGraw, Steven, Jaeckle, Kurt A, Flynn, Patrick J, Ligon, Keith L, Buckner, Jan C, Sarkaria, Jann N

“…The mammalian target of rapamycin (mTOR) functions within the phosphatidylinositol-3 kinase (PI3K)/Akt pathway as a critical modulator of cell survival. This…”
Get full text

Clinical, Neurophysiologic, and Pathologic Features in Patients With Early-Onset Postradiation Neuropathy by Skolka, Michael, Shelly, Shahar, Pinto, Marcus V, Dubey, Divyanshu, Oishi, Tatsuya, Uhm, Joon H, Santilli, Ashley, Staff, Nathan P, Spinner, Robert J, Dyck, P James B, Robertson, Carrie Elizabeth, Klein, Christopher J

“…The objective of this study was to study early-onset radiation-induced neuropathy reviewing neurologic course, steroid response, and available nerve biopsies…”
Get full text

Management and Long-term Outcomes of Adults With Medulloblastoma: A Single-Center Experience by Neth, Bryan J, Raghunathan, Aditya, Kizilbash, Sani H, Uhm, Joon H, Breen, William G, Johnson, Derek R, Daniels, David J, Sener, Ugur, Carabenciov, Ivan D, Campian, Jian L, Khatua, Soumen, Mahajan, Anita, Ruff, Michael W

“…Medulloblastomas are embryonal tumors predominantly affecting children. Recognition of molecularly defined subgroups has advanced management. Factors…”
Get full text

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas by Van Gompel, Jamie J, Agazzi, Siviero, Carlson, Matthew L, Adewumi, Dare A, Hadjipanayis, Constantinos G, Uhm, Joon H, Olson, Jeffrey J

“…Abstract MEDICAL THERAPY Target Population Adults with histologically proven or suspected vestibular schwannomas with neurofibromatosis type 2 (NF2). Question…”
Get full text